Statements (18)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:acquisitionYear |
2015
|
| gptkbp:CEO |
gptkb:Sanford_D._Smith
|
| gptkbp:focusesOn |
orphan drugs
rare diseases |
| gptkbp:foundedBy |
gptkb:Sanford_D._Smith
|
| gptkbp:foundedYear |
2000
|
| gptkbp:headquartersLocation |
gptkb:Lexington,_Massachusetts,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Synageva BioPharma
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableProduct |
sebelipase alfa
|
| gptkbp:numberOfEmployees |
approximately 300 (at time of acquisition)
|
| gptkbp:stockSymbol |
gptkb:GEVA
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.synageva.com
|
| gptkbp:bfsParent |
gptkb:Alexion_Pharmaceuticals
|
| gptkbp:bfsLayer |
6
|